The costs of dementia -- economic and personal -- are staggering. A recent RAND analysis quantifies the scope of the problem in the United States and serves as a wake-up call to policymakers everywhere.
The authors use a simulation model that quantifies the capacity of the Canadian health care system to diagnose and treat people with early-stage Alzheimer's disease should a disease-modifying therapy become available.
Paradoxical lucidity, challenges current assumptions and highlights the possibility of network-level return of cognitive function in cases of severe dementias, which can provide insight into both underlying neurobiology and future therapeutic possibilities.
The 33 studies reviewed identify multiple workforce-related challenges for families seeking treatment for children with autism spectrum disorder-including lack of primary care providers to serve these children, lack of specialty providers, and sociodemographic and geographic disparities in access to ASD services.
The Seventh Department of Defense State-of-the-Science Meeting examined the risk posed to military personnel by low-level blast exposure, the current evidence base, and potentially promising approaches to prevent and detect blast injuries.
This issue spotlights (1) research on how faith-based organizations promote health and well-being in underserved communities and (2) the Pardee RAND Graduate School's new approach to policy and training the next generation of policy experts.
This paper estimates cumulative lifetime medical expenditures that can be attributed to the onset of dementia using a nationally representative longitudinal survey from the U.S., the Health and Retirement Study.
This issue spotlights RAND's research on how providers can better meet the health care needs of veterans; life as a U.S. Army private; and Air Force efforts to improve leadership opportunities for women.
Jodi Liu, an associate policy researcher at RAND, studies how to deliver high-quality care and how to pay for it. She discusses her assessment of a single-payer health care proposal in New York State and the supply-and-demand challenges that might arise if an Alzheimer's treatment became available.
The health care systems in some European countries lack the capacity to rapidly move a disease-modifying treatment for Alzheimer's disease from approval into widespread clinical use, which could leave 1 million people without access to transformative care if such a breakthrough occurs.
A therapy for early-stage Alzheimer's disease could be available by 2020, but millions of European patients might have to wait a year or more for initial appointments in the multistep process if health care system capacity is not increased.
A potential therapy for early-stage Alzheimer's patients might prevent or delay the progression to dementia. An assessment of how prepared six European nations are to deliver such a therapy indicates a pressing need to address health system constraints. One million patients could develop the disease while waiting for treatment.
Among Americans aged 55-69, rates of cognitive limitation are many times higher for groups with lower socioeconomic status (SES) than those with higher SES, and recent trends show little indication that gaps are narrowing.
A nationally representative study of 16,000 U.S. seniors is the first to show that dementia and cognitive impairment are more common among rural seniors than their urban peers. However, rural investments in boosting high school graduation rates have narrowed the gap.
The U.S. health care system lacks the capacity to rapidly move a treatment for Alzheimer's disease from approval into wide clinical use, a shortcoming that could leave millions of people without access to transformative care if such a breakthrough occurs.
Drugs to halt the progression of Alzheimer's disease may be available by 2020, but millions of U.S. patients might have to wait more than 14 months for initial appointments in the multistep process unless health care system capacity is increased.
The U.S. health care system isn't ready to meet demand for a breakthrough Alzheimer's treatment. Results from clinical trials are producing guarded optimism that a breakthrough could arrive as early as 2020. If this happens, up to 2.1 million patients could develop Alzheimer's dementia by 2040 while on treatment and evaluation waiting lists.